West Pharmaceutical Services (WPS) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

WPS Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

West

Pharmaceutical Services

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WPS Stock 12 Month Forecast

Average Price Target

€352.89

▲(13.83% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is €352.89 with a high forecast of €391.66 and a low forecast of €319.81. The average price target represents a 13.83% change from the last price of €310.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"182":"€182","287":"€287","392":"€392","234.5":"€234.5","339.5":"€339.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":391.65692106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€391.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":352.885514445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€352.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":319.8093427,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€319.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[182,234.5,287,339.5,392],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.491,317.65760931230767,323.82421862461536,329.9908279369231,336.1574372492308,342.32404656153847,348.49065587384615,354.65726518615384,360.8238744984615,366.9904838107692,373.15709312307695,379.32370243538463,385.4903117476923,{"y":391.65692106,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.491,314.67519341884616,317.8593868376923,321.04358025653846,324.2277736753846,327.41196709423076,330.59616051307694,333.78035393192306,336.96454735076924,340.1487407696154,343.33293418846154,346.5171276073077,349.70132102615383,{"y":352.885514445,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.491,312.1308725153846,312.7707450307692,313.41061754615384,314.0504900615384,314.69036257692306,315.3302350923077,315.9701076076923,316.6099801230769,317.24985263846156,317.88972515384614,318.5295976692308,319.16947018461536,{"y":319.8093427,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":183.374,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.451,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":208.448,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.212,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.354,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231.562,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.081,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.401,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.297,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.531,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.115,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.491,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€391.66

Average Price Target€352.89

Lowest Price Target€319.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Daniel Markowitz CFA

Evercore ISI

€359.24→€372.38

Buy

20.12%

Upside

Reiterated

07/27/26

West Pharmaceutical price target raised to $425 from $410 at Evercore ISIWest Pharmaceutical price target raised to $425 from $410 at Evercore ISI

Luke Sergott

Barclays

€350.48

Buy

13.06%

Upside

Reiterated

07/24/26

West Pharmaceutical Services (WST) Receives a Buy from Barclays

Michael Ryskin

Bank of America Securities

€359.24

Buy

15.88%

Upside

Reiterated

07/24/26

West Pharmaceutical price target raised to $410 from $400 at BofAWest Pharmaceutical price target raised to $410 from $400 at BofA

Brendan Smith

TD Cowen

€319.81→€359.24

Buy

15.88%

Upside

Assigned

07/23/26

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST) and Thermo Fisher (NYSE: TMO)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/23/26

Analyst Reiterates Buy on West as Biologics-Driven Double-Digit Growth, Margin Upside and Conservative Outlook Signal Further Upside Potential

Curtis Moiles

Exane BNP Paribas

€391.66

Buy

26.34%

Upside

Initiated

07/13/26

West Pharmaceutical initiated with an Outperform at BNP ParibasWest Pharmaceutical initiated with an Outperform at BNP Paribas

Kallum Titchmarsh

Morgan Stanley

€284.76→€319.81

Hold

3.16%

Upside

Assigned

07/09/26

West Pharmaceutical price target raised to $365 from $325 at Morgan StanleyWest Pharmaceutical price target raised to $365 from $325 at Morgan Stanley

Paul Knight

KeyBanc

€306.67→€341.71

Buy

10.23%

Upside

Reiterated

07/02/26

West Pharmaceutical price target raised to $390 from $350 at KeyBancWest Pharmaceutical price target raised to $390 from $350 at KeyBanc

Michael Polark

Wolfe Research

€328.57

Buy

5.99%

Upside

Assigned

06/01/26

West Pharmaceutical assumed at Outperform from Peer Perform at Wolfe ResearchWest Pharmaceutical assumed at Outperform from Peer Perform at Wolfe Research

Patrick B Donnelly

Citi

€328.57→€350.48

Buy

13.06%

Upside

Reiterated

04/24/26

West Pharmaceutical price target raised to $400 from $375 at CitiWest Pharmaceutical price target raised to $400 from $375 at Citi

Dan Leonard

RBC Capital

€311.05→€297.9

Buy

-3.90%

Downside

Reiterated

02/13/26

West Pharmaceutical price target lowered to $340 from $355 at UBSWest Pharmaceutical price target lowered to $340 from $355 at UBS

Justin Bowers

Deutsche Bank

€271.62→€276

Buy

-10.97%

Downside

Reiterated

02/13/26

West Pharmaceutical price target raised to $315 from $310 at Deutsche BankWest Pharmaceutical price target raised to $315 from $310 at Deutsche Bank

David Windley

Jefferies

€319.81→€258.48

Buy

-16.62%

Downside

Reiterated

02/10/26

Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)

Nico Chen

DBS

€280.38

Buy

-9.55%

Downside

Reiterated

01/28/26

DBS Sticks to Their Buy Rating for West Pharmaceutical Services (WST)

Thomas DeBourcy

Nephron

€321.56

Buy

3.73%

Upside

Upgraded

12/11/25

West Pharmaceutical upgraded to Buy from Hold at Nephron ResearchWest Pharmaceutical upgraded to Buy from Hold at Nephron Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Daniel Markowitz CFA

Evercore ISI

€359.24→€372.38

Buy

20.12%

Upside

Reiterated

07/27/26

West Pharmaceutical price target raised to $425 from $410 at Evercore ISIWest Pharmaceutical price target raised to $425 from $410 at Evercore ISI

Luke Sergott

Barclays

€350.48

Buy

13.06%

Upside

Reiterated

07/24/26

West Pharmaceutical Services (WST) Receives a Buy from Barclays

Michael Ryskin

Bank of America Securities

€359.24

Buy

15.88%

Upside

Reiterated

07/24/26

West Pharmaceutical price target raised to $410 from $400 at BofAWest Pharmaceutical price target raised to $410 from $400 at BofA

Brendan Smith

TD Cowen

€319.81→€359.24

Buy

15.88%

Upside

Assigned

07/23/26

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST) and Thermo Fisher (NYSE: TMO)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/23/26

Analyst Reiterates Buy on West as Biologics-Driven Double-Digit Growth, Margin Upside and Conservative Outlook Signal Further Upside Potential

Curtis Moiles

Exane BNP Paribas

€391.66

Buy

26.34%

Upside

Initiated

07/13/26

West Pharmaceutical initiated with an Outperform at BNP ParibasWest Pharmaceutical initiated with an Outperform at BNP Paribas

Kallum Titchmarsh

Morgan Stanley

€284.76→€319.81

Hold

3.16%

Upside

Assigned

07/09/26

West Pharmaceutical price target raised to $365 from $325 at Morgan StanleyWest Pharmaceutical price target raised to $365 from $325 at Morgan Stanley

Paul Knight

KeyBanc

€306.67→€341.71

Buy

10.23%

Upside

Reiterated

07/02/26

West Pharmaceutical price target raised to $390 from $350 at KeyBancWest Pharmaceutical price target raised to $390 from $350 at KeyBanc

Michael Polark

Wolfe Research

€328.57

Buy

5.99%

Upside

Assigned

06/01/26

West Pharmaceutical assumed at Outperform from Peer Perform at Wolfe ResearchWest Pharmaceutical assumed at Outperform from Peer Perform at Wolfe Research

Patrick B Donnelly

Citi

€328.57→€350.48

Buy

13.06%

Upside

Reiterated

04/24/26

West Pharmaceutical price target raised to $400 from $375 at CitiWest Pharmaceutical price target raised to $400 from $375 at Citi

Dan Leonard

RBC Capital

€311.05→€297.9

Buy

-3.90%

Downside

Reiterated

02/13/26

West Pharmaceutical price target lowered to $340 from $355 at UBSWest Pharmaceutical price target lowered to $340 from $355 at UBS

Justin Bowers

Deutsche Bank

€271.62→€276

Buy

-10.97%

Downside

Reiterated

02/13/26

West Pharmaceutical price target raised to $315 from $310 at Deutsche BankWest Pharmaceutical price target raised to $315 from $310 at Deutsche Bank

David Windley

Jefferies

€319.81→€258.48

Buy

-16.62%

Downside

Reiterated

02/10/26

Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)

Nico Chen

DBS

€280.38

Buy

-9.55%

Downside

Reiterated

01/28/26

DBS Sticks to Their Buy Rating for West Pharmaceutical Services (WST)

Thomas DeBourcy

Nephron

€321.56

Buy

3.73%

Upside

Upgraded

12/11/25

West Pharmaceutical upgraded to Buy from Hold at Nephron ResearchWest Pharmaceutical upgraded to Buy from Hold at Nephron Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering West Pharmaceutical Services

3 Months

Matt LarewWilliam Blair

Success Rate

7/10 ratings generated profit

Average Return

+11.73%

Copying Matt Larew's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +11.73% per trade.

1 Year

Patrick B DonnellyCiti

Success Rate

6/7 ratings generated profit

Average Return

+18.31%

Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +18.31% per trade.

2 Years

Nico ChenDBS

Success Rate

6/6 ratings generated profit

Average Return

+27.18%

Copying Nico Chen's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +27.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WPS Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WPS has received 17 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. WPS average Analyst price target in the past 3 months is 352.89.

Each month's total comprises the sum of three months' worth of ratings.

WPS Financial Forecast

WPS Earnings Forecast

Next quarter’s earnings estimate for WPS is €1.92 with a range of €1.85 to €1.95. The previous quarter’s EPS was €2.08. WPS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year WPS has Performed in-line its overall industry.

WPS Sales Forecast

Next quarter’s sales forecast for WPS is €723.90M with a range of €714.35M to €728.38M. The previous quarter’s sales results were €765.86M. WPS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 29.50% of the time in the same period. In the last calendar year WPS has Performed in-line its overall industry.

WPS Stock Forecast FAQ

What is DE:WPS’s average 12-month price target, according to analysts?

Based on analyst ratings, West Pharmaceutical Services, Inc.’s 12-month average price target is 352.89.

What is DE:WPS’s upside potential, based on the analysts’ average price target?

West Pharmaceutical Services, Inc. has 13.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is West Pharmaceutical Services, Inc. a Buy, Sell or Hold?

West Pharmaceutical Services, Inc. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is West Pharmaceutical Services, Inc.’s share price target?

The average share price target for West Pharmaceutical Services, Inc. is 352.89. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €391.66 ,and the lowest forecast is €319.81. The average share price target represents 13.83% Increase from the current price of €310.

What do analysts say about West Pharmaceutical Services, Inc.?

West Pharmaceutical Services, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of West Pharmaceutical Services, Inc.?

To buy shares of DE:WPS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

West Pharmaceutical Services (WPS) Stock Forecast & Price Target

WPS Analyst Ratings

WPS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering West Pharmaceutical Services

WPS Analyst Recommendation Trends

WPS Financial Forecast

WPS Earnings Forecast

WPS Sales Forecast

WPS Stock Forecast FAQ

Detailed List of Analyst Forecasts